SCHEMBL15426992

SCHEMBL15426992

COc1cc2c(c(OC)c1OC)C(c1cc(Cl)ccc1F)CC(=O)N2

nearest known ligand 0.74

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.74
SMN1; SMN2 Q16637 4/20 0.64
ALDH1A1 P00352 3/20 0.64
GAA P10253 1/20 0.64
HTT P42858 1/20 0.64
TSHR P16473 3/20 0.60
MAPK1 P28482 2/20 0.60
RECQL P46063 1/20 0.60
LMNA P02545 3/20 0.57
KDM4E B2RXH2 1/20 0.55
HPGD P15428 1/20 0.55
TP53 P04637 1/20 0.50
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15427042 0.90 MAPT (0.67) MAPTSMN1; SMN2ALDH1A1GAAHTT
SCHEMBL15427014 0.90 SMN1; SMN2 (0.65) MAPTSMN1; SMN2ALDH1A1GAAHTT
SCHEMBL15427041 0.89 MAPT (0.66) MAPTSMN1; SMN2ALDH1A1GAAHTT
SCHEMBL19270422 0.89 MAPT (0.74) MAPTSMN1; SMN2ALDH1A1GAAHTT
SCHEMBL30162895 0.88 SMN1; SMN2 (0.63) MAPTSMN1; SMN2ALDH1A1GAAHTT
SCHEMBL15427005 0.88 SMN1; SMN2 (0.63) MAPTSMN1; SMN2ALDH1A1GAAHTT
SCHEMBL19270407 0.88 MAPT (0.58) MAPTSMN1; SMN2ALDH1A1GAAHTT
SCHEMBL15427001 0.88 MAPT (0.72) MAPTSMN1; SMN2ALDH1A1GAAHTT
SCHEMBL19270409 0.87 MAPT (0.71) MAPTSMN1; SMN2ALDH1A1GAAHTT
SCHEMBL15426986 0.86 ALDH1A1 (0.71) MAPTSMN1; SMN2ALDH1A1GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10420753-B2 Combination therapies for treatment of spinal muscular atrophy INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2019-09-24 US disclosed
US-9895358-B2 Combination therapies for treatment of spinal muscular atrophy INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-02-20 US disclosed
US-9895358-B2 Combination therapies for treatment of spinal muscular atrophy INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-02-20 US disclosed
WO-2017147312-A1 COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2017-08-31 WO disclosed
US-20170239225-A1 COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2017-08-24 US disclosed
US-20170239225-A1 COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2017-08-24 US disclosed
US-20160052935-A1 COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY THE UNIVERSITY OF MASSACHUSETTS 2016-02-25 US disclosed
US-20160052935-A1 COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY THE UNIVERSITY OF MASSACHUSETTS 2016-02-25 US disclosed
US-9212209-B2 Screening methods for spinal muscular atrophy INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-15 US disclosed
US-9212209-B2 Screening methods for spinal muscular atrophy INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-15 US disclosed
US-20140193906-A1 SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY THE UNIVERSITY OF MASSACHUSETTS 2014-07-10 US disclosed
US-20140193906-A1 SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY THE UNIVERSITY OF MASSACHUSETTS 2014-07-10 US disclosed
WO-2014012050-A2 COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052935-A1 COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, MTPN MAPT 1135/4885SMN1; SMN2 1/4885ALDH1A1 1231/4885
US-10420753-B2 Combination therapies for treatment of spinal muscular atrophy SMN1; SMN2, MUSK, MYOF MAPT 523/4885SMN1; SMN2 1/4885ALDH1A1 2026/4885
US-20170239225-A1 COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY SMN1; SMN2, MUSK, MYOF MAPT 523/4885SMN1; SMN2 1/4885ALDH1A1 2026/4885
US-20140193906-A1 SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY SMN1; SMN2, MYOF, MTPN MAPT 800/4885SMN1; SMN2 1/4885ALDH1A1 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.